Pfizer cuts €400M plant expansion after dumping cholesterol-lowering drug program

A proposed expansion of a Pfizer plant in Ireland is being scaled back.

Earlier this month, Pfizer dumped development of a new cholesterol-lowering drug candidate that had not lived up to expectations in a late-phase trial. Now Pfizer is dumping much of the €400 million plant expansion in Ireland it was planning to support it.

With the decision not to proceed with the proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) bococizumab, the New York drugmaker will not need the 371,300-square-foot expansion of its Grange Castle biologics manufacturing unit or the 300 or so jobs that would have brought, the Irish Times reported today.  

A company spokeswoman pointed out in an email today that Pfizer had never confirmed an expansion, only that it had submitted plans for one to authorities in Ireland. It said today it will still do a smaller version of the expansion for production of other drugs at the massive site, where it currently employs about 1,100 workers.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

“Following the decision to discontinue the development of bococizumab, part of the potential expansion for which the planning permission was sought will not now go ahead,” she said. “Expansion in relation to other incoming products will continue as planned, involving investment, recruitment and new technology.”

When Pfizer confirmed last summer that it was contemplating a $423 million expansion of the facility, it said the project would be completed in two phases, adding 200 jobs to Pfizer’s Ireland operations with the initial phase and another 100 jobs upon completion of the second.

That changed when the drug giant announced this month that it found that bococizumab “is not likely to provide value to patients, physicians, or shareholders” after data showed its ability to lower LDL-C weakened over time and increased the risk of some adverse events. It said that “taken together with the evolving treatment and market landscape for lipid-lowering agents,” it had decided to discontinue the development program, including the two ongoing cardiovascular outcome studies.

That leaves the field to Amgen and partners Sanofi and Regeneron, which already have PCSK9 cholesterol-fighters Repatha and Praluent on the market. But the “market landscape” Pfizer referred to includes the fact that payers have slapped prior-authorization hurdles on the drugs and uptake has not been what was originally anticipated. Many doctors say they're waiting for more data that would show whether Praluent and Repatha significantly cut the risk of cardiovascular events such as heart attacks, data that would change their thinking on use significantly.

Suggested Articles

FDA officials say Novartis took too long to launch a formal probe into allegations of Zolgensma data manipulation.

Should Johnson & Johnson owe billions to fix Oklahoma's opioid crisis? After weeks of trial testimony, a judge will have his say Monday afternoon.

After Endo and Allergan agreed to settle with two Ohio counties on opioid charges this week, the state’s AG has a message: You’re not off the hook.